Oragenics (OGEN) Competitors $1.10 -0.02 (-1.34%) Closing price 03:56 PM EasternExtended Trading$1.12 +0.01 (+0.90%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. SYBX, PMN, CMMB, MBRX, XFOR, LSB, EDSA, HOTH, LIXT, and LPCNShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Synlogic (SYBX), Promis Neurosciences (PMN), Chemomab Therapeutics (CMMB), Moleculin Biotech (MBRX), X4 Pharmaceuticals (XFOR), LakeShore Biopharma (LSB), Edesa Biotech (EDSA), Hoth Therapeutics (HOTH), Lixte Biotechnology (LIXT), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors Synlogic Promis Neurosciences Chemomab Therapeutics Moleculin Biotech X4 Pharmaceuticals LakeShore Biopharma Edesa Biotech Hoth Therapeutics Lixte Biotechnology Lipocine Synlogic (NASDAQ:SYBX) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Which has more risk & volatility, SYBX or OGEN? Synlogic has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Is SYBX or OGEN more profitable? Synlogic's return on equity of -8.09% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -8.09% -5.50% Oragenics N/A -2,087.95%-486.56% Which has preferable valuation and earnings, SYBX or OGEN? Oragenics has lower revenue, but higher earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$10K1,708.20-$23.36M-$2.51-0.58OragenicsN/AN/A-$20.66M-$21.42-0.05 Do insiders & institutionals believe in SYBX or OGEN? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 3.0% of Synlogic shares are held by company insiders. Comparatively, 4.9% of Oragenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer SYBX or OGEN? In the previous week, Synlogic had 1 more articles in the media than Oragenics. MarketBeat recorded 1 mentions for Synlogic and 0 mentions for Oragenics. Synlogic's average media sentiment score of 1.87 beat Oragenics' score of 0.00 indicating that Synlogic is being referred to more favorably in the media. Company Overall Sentiment Synlogic Very Positive Oragenics Neutral SummarySynlogic beats Oragenics on 7 of the 11 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.56M$853.28M$5.74B$21.27BDividend YieldN/A4.84%4.40%3.53%P/E Ratio-0.161.1630.8329.22Price / SalesN/A138.93382.9052.82Price / CashN/A19.5637.7223.61Price / Book1.816.7710.105.36Net Income-$20.66M-$4.20M$3.26B$996.59M7 Day Performance2.31%11.77%3.90%3.11%1 Month Performance-20.50%3.47%3.73%3.23%1 Year Performance-97.10%15.88%37.68%11.54% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.1412 of 5 stars$1.11-1.3%N/A-96.3%$4.56MN/A-0.165SYBXSynlogic1.1438 of 5 stars$1.49+6.1%N/A+0.7%$17.37M$10K-0.5980Positive NewsPMNPromis Neurosciences3.2356 of 5 stars$0.52-7.3%$4.33+727.0%-56.4%$17.36MN/A-2.535Positive NewsCMMBChemomab Therapeutics3.2543 of 5 stars$0.91-2.7%$8.50+839.2%-46.2%$17.07MN/A-1.5320News CoverageAnalyst ForecastMBRXMoleculin Biotech2.8805 of 5 stars$0.56-6.1%$4.00+614.3%-78.6%$16.96MN/A0.0020Analyst ForecastGap DownXFORX4 Pharmaceuticals4.1165 of 5 stars$2.92-0.5%$71.17+2,341.4%-79.1%$16.88M$2.56M-0.2080LSBLakeShore Biopharma1.5248 of 5 stars$0.81-1.1%N/A-82.1%$16.84M$614.96M0.00773Positive NewsEDSAEdesa Biotech1.5781 of 5 stars$2.39+3.0%$5.00+109.2%-45.6%$16.83MN/A-1.8120HOTHHoth Therapeutics2.788 of 5 stars$1.26-0.8%$4.00+217.5%+60.4%$16.71MN/A-1.184Positive NewsLIXTLixte Biotechnology0.1665 of 5 stars$3.54+1.6%N/A+72.0%$16.16MN/A-2.754LPCNLipocine2.3966 of 5 stars$3.00+1.3%$9.00+200.1%-15.3%$16.15M$11.20M-3.4210News Coverage Related Companies and Tools Related Companies Synlogic Competitors Promis Neurosciences Competitors Chemomab Therapeutics Competitors Moleculin Biotech Competitors X4 Pharmaceuticals Competitors LakeShore Biopharma Competitors Edesa Biotech Competitors Hoth Therapeutics Competitors Lixte Biotechnology Competitors Lipocine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access